Trial intelligence / Profile preview

Five-day versus usual-duration moxifloxacin for hospitalized community-acquired pneumonia with high PSI score

2017-001406-15Phase 4Active

Sponsor
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
Start
Apr 2018
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4 trial of moxifloxacin in community-acquired pneumonia (CAP) (2 arms), sponsored by Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer. Primary endpoint: Rate of treatment failure during the first 30 days after hospital admission. Started Apr 2018; status: active.

02

Drugs

moxifloxacin
03

Conditions

community-acquired pneumonia (CAP)

Beyond the preview

Go deeper on 2017-001406-15.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2017-001406-15.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call